Controversies in the Diagnosis and Treatment of Severe Depression
J Clin Psychiatry 1996;57(11):554-561
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Severe depression is a frequently diagnosed disorder and a major health problem in the United States and Europe. An international panel of experts met recently in New Paltz, New York, to discuss whether severe depression constitutes a distinct form of depression and to review effective treatments for the disorder. In his opening remarks, Roger Pinder, Ph.D., D.Sc., Medical Director CNS at N.V. Organon, said, “Severe depression is a major topic for discussion at the present time. There is a feeling, with some evidence, that patients with this disorder respond less well to SSRIs, suggesting that severe depression may be better served by using drugs like the tricyclic antidepressants or drugs that have a dual mechanism of action.”